From Nasdaq MarketSite: 2025-04-01 22:33:00

Johnson & Johnson is set to complete its acquisition of Intra-Cellular Therapies around April 2, 2025, following shareholder approval. The acquisition is expected to boost Johnson & Johnson’s 2025 sales growth by 0.8% with $0.7 billion in incremental sales. Adjusted earnings per share for 2025 are estimated to improve by $0.25, with a reduced earnings dilution of about $0.21 in 2026. These figures will be included in Johnson & Johnson’s full-year 2025 financial outlook, to be reported on April 15, 2025. After the transaction, Intra-Cellular Therapies’ stock will no longer trade on the NASDAQ Global Select Market.



Read more at Nasdaq MarketSite: Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025